Kefah Mokbel: Study Reveals Cancer Risks Associated With Pathogenic PALB2 Variants
Kefah Mokbel/ LinkedIn

Kefah Mokbel: Study Reveals Cancer Risks Associated With Pathogenic PALB2 Variants

Kefah Mokbel, Professor of Medicine (Honorary) at Cardiff University School of Medicine, shared on LinkedIn:

“What does a pathogenic PALB2 variant mean for a woman who learns she carries it through population testing?

Many of the risk estimates we use in clinic come from families referred for genetic testing because of their cancer history.

A new study by Douglas Stewart and colleagues in JNCI examined exome sequencing data from more than 636,000 participants in UK Biobank and Geisinger MyCode. Participants were included regardless of their personal or family history of cancer.

Across both cohorts, carriers of a pathogenic or likely pathogenic PALB2 variant had higher odds of female breast cancer and pancreatic cancer. Carriers also had higher all-cause mortality (adjusted hazard ratios 1.61–1.67). Cancer risk estimates were lower than those reported in studies of families referred for genetic testing, and family history further influenced risk.

My clinical takeaway: When counselling a woman with a pathogenic PALB2 variant, I would want to know how the variant came to light, which relatives developed cancer, and at what ages. Those details matter when discussing her absolute breast cancer risk, enhanced surveillance, and the option of risk-reducing surgery.”

You can also read: PRECEDE Study: Pancreatic Imaging Findings During Surveillance in BRCA1, BRCA2, ATM, and PALB2 Heterozygotes

Kefah Mokbel: Study Reveals Cancer Risks Associated With Pathogenic PALB2 Variants